Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.

EZ Weight Loss TX LLC Issues Voluntary Nationwide Recall Of Atomic And Xplode Capsules

All lots and codes of Atomic and Xplode are included in this recall and were sold Nationwide starting in 2015.

Corpus Christi, TX, EZ Weight Loss TX is voluntarily recalling all lots of La Bri’s Body Health Atomic and Xplode capsules to the consumer level. FDA analysis has found the products to be tainted with sibutramine.

Sibutramine is an appetite suppressant that was withdrawn from the U.S. market in October 2010 for safety reasons. The presence of sibutramine in these products renders it an unapproved drug for which safety and efficacy have not been established and, therefore subject to recall.

Sibutramine is known to increase blood pressure and/or pulse rate in some patients and may present a risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. Sibutramine may also interact, in life-threatening ways with other medications a consumer may be taking. To date, EZ Weight Loss TX has not received any reports of adverse events related to this recall.

These tainted products are marketed as dietary supplements. Atomic is packaged in 60- count bottles and Xplode is packaged in 30-count bottles. All lots and codes of Atomic and Xplode are included in this recall and were sold Nationwide through internet sales starting in 2015.

EZ Weight Loss TX is asking its customers to contact them via email or phone to arrange for a return or refund of any unused portion or replacement on these recalled products. Consumers that have these products should stop using immediately.

Consumers with questions regarding this recall can contact EZ Weight Loss TX at 361-334-1977 Monday-Saturday from 11:00 am-6:30 pm CST or e-mail ezweightlosstx@gmail.com. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these drug products.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.


 

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button